CompanyIntelligence | Merck & Co., Inc.

The Consus Group provides critical intelligence for the
business, investor, and legal communities.

Documents can be downloaded immediately after purchase. Complete your order by clicking the Add-to-Cart button.

$41	Subscribers Preview	2001	Agilent Technologies and Merck to Continue Alliance for Development of Gene Expression Analysis Solutions	Merck & Co., Inc.
$63	Subscribers Preview	2003	Agreement	KV Pharmaceutical Co.; FemmePharma, Inc.; AstraZeneca	K-V Pharma; Merck; Pharmacia
$38	Subscribers Preview	2003	Agreement	Edward M. Scolnick	Merck & Co., Inc.
$61	Subscribers Preview	2004	Agreement	Robert L. Hunter; CytRx; Merck	Progenics; Vical
$38	Subscribers Preview	2003	Biomarin Accelerates Development of Phenoptin, a Novel Oral Enzyme Cofactor for the Treatment of PKU	BioMarin Pharmaceutical Inc.	Merck & Co., Inc.
$39	Subscribers Preview	2004	Biomarin Assembles Leading Metabolic Disease Experts to Guide Its PKU Product Development Program	BioMarin Pharmaceutical Inc.	Merck & Co., Inc.
$42	Subscribers Preview	2002	Broadened Portfolio of Breakthrough Medicines Will Drive Merck's Growth	Medco Health; Merck	Schering-Plough
$39	Subscribers Preview	2003	Cambridge Antibody Technology and Amgen Restructure Existing Agreement	Immunex Corporation; Amgen; CATG	Human Genome; Merck
$40	Subscribers Preview	2003	Cambridge Antibody Technology and Dyax Corp. Further Expand Licencing Agreement	CATG; Dyax	Human Genome; Merck
$31	Subscribers Preview	2003	Cambridge Antibody Technology and Dyax Expand Licensing Agreement	CATG; Dyax; Human Genome	Merck; Wyeth
$40	Subscribers Preview	2002	Cambridge Antibody Technology Broadens Relationship with Merck & Co., Inc.	CATG; Human Genome	Merck; Wyeth
$40	Subscribers	2004	Cambridge Antibody Technology Grants Licence to Wyeth	CATG; Human Genome	Merck; Wyeth
$35	Subscribers Preview	2002	Cambridge Antibody Technology Interim Results for the Six Months Ended 31 March 2002	Abbott Labs; CATG; Celera Genomics	Human Genome; Merck; Wyeth
$49	Subscribers Preview	2004	Cambridge Antibody Technology Interim Results for the Six Months Ended 31 March 2004	Abbott Labs; Amgen; CATG	Human Genome; Merck; Wyeth
$36	Subscribers Preview	2003	Cambridge Antibody Technology Reports Granting of Positive Opinion for Humiratm by European Medicines Evaluation Agency	Abbott Labs; CATG; Human Genome	Merck; Wyeth
$35	Subscribers Preview	2002	Cholesterol Governance Agreement [Amendment No. 1]	Merck & Co., Inc.	Schering-Plough Corp.
$38	Subscribers Preview	2002	Closing Remarks for Raymond V. Gilmartin Chairman, President and CEO, Merck & Co., Inc. at 2002 Annual Business Briefing	Merck & Co., Inc.
$39	Subscribers Preview	2003	Closing Remarks of Raymond V. Gilmartin, Chairman, President, and Chief Executive Officer, Merck & Co., Inc. at the 2003 Annual Business Briefing	Merck & Co., Inc.
$35	Subscribers	2001	Cubist Pharmaceuticals and DSM Fine Chemicals Announce Opening of Daptomycin Manufacturing Facility	Cubist Pharma; Gilead Sciences	Merck; Novartis Pharma
$39	Subscribers	2001	Cubist Pharmaceuticals and Gilead Sciences Announce European Commercialization Agreement for Investigational Antibacterial Agent Cidecin(TM)	Cubist Pharma; Gilead Sciences; Merck	Novartis Pharma; Schering-Plough